Colon Carcinoma Clinical Trial
Official title:
Trained Immunity of Myeloid Cells and Their Progenitors in Patients With Non-medullary Thyroid Carcinoma and Colon Carcinoma
Verified date | November 2023 |
Source | Radboud University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Tumor-related inflammation is one of the hallmarks of cancers in general. Innate immunity specifically is a common denominator which is involved in the pathogenesis of both thyroid carcinoma and colon carcinoma. To improve the patient's outcome and identify novel therapeutic targets, one needs a deeper understanding of the tumor-induced changes in the bone marrow myeloid progenitor cells. Furthermore, treatment of these cells by nanoparticles or other agents that induce a program of 'trained immunity' may be a novel way to re-educate myeloid cells and their bone marrow progenitors in thyroid carcinoma patients. Lastly, the investigators expect that this approach could be effective also in other cancers of which colon carcinoma is here proposed as an additional model. The investigators hypothesize that by exposing myeloid cells or their progenitors to various agents that induce trained immunity (e.g. high-density-lipoprotein-methylene diphosphonate nanoparticles, recombinant and synthetic cytokines), these immune cells will undergo functional reprogramming to induce a tumor-suppressive phenotype. In the future, this could be explored as a novel immunotherapy for tumors that are refractory to conventional treatment.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | April 7, 2025 |
Est. primary completion date | September 7, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - At least 18 years old and mentally competent - Newly diagnoses non-medullary thyroid carcinoma or colon carcinoma that is therapy naïve - Planned to receive conventional treatment for the malignancy by surgery Exclusion Criteria: - Mentally incompetent - Pregnant or breastfeeding - Known inflammation or infectious disease or an immunosuppressive status - Using medication interfering with the immune system - Reduced platelets counts or other conditions associated with an increased risk of bleeding - Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas) - Previous anti-cancer treatment, such as chemotherapy, radiotherapy or surgical removal or the primary tumor - Serious psychiatric pathology - A self-reported alcohol consumption of >21 units per week |
Country | Name | City | State |
---|---|---|---|
Netherlands | RadboudUMC | Nijmegen | Gelderland |
Lead Sponsor | Collaborator |
---|---|
Radboud University Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Age of subjects | Age in years of subjects | At baseline | |
Other | Length of subjects | Length in meters of subjects | At baseline | |
Other | Weight of subjects | Weight in kilograms of subjects | Through study completion, an average of 1 year | |
Other | Thyroid stimulating hormone | Levels of thyroid stimulating hormone (TSH), measured in mili unit/Liter. Only measured in the patients with thyroid carcinoma. | At baseline | |
Other | Carcino-embryonal antigen | Levels of carcino-embryonal antigen (CEA), measured in ug/Liter. Only measured in patients with colon carcinoma. | At baseline | |
Primary | Levels of pro-inflammatory cytokines en chemokines | Levels of pro-inflammatory cytokines en chemokines such as tumor necrosis factor-alfa,interleukin(IL)-1beta and IL-6 will be measured (pg/miliLiter) before and after induction of trained immunity. This will happen after 1 and after 7 days. These will be measured using ELISA. | After 7 days. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01896778 -
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
|
N/A | |
Terminated |
NCT01111292 -
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT00996619 -
Measuring the Spectrum of Tissues During Endoscopy
|
N/A | |
Withdrawn |
NCT03408561 -
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
|
N/A | |
Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
Active, not recruiting |
NCT02991092 -
The Influence of Different Fluid Therapy Measures on the Postoperative Outcome in Fast Track of Colon Cancer.(FTSlapCC)
|
N/A | |
Active, not recruiting |
NCT01696981 -
Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)
|
N/A | |
Terminated |
NCT03137706 -
Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
|
||
Active, not recruiting |
NCT03151564 -
Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques
|
N/A | |
Recruiting |
NCT04959604 -
Lymph Node Mapping Via Flourescent Dye in Colon Cancer
|
N/A | |
Completed |
NCT02890758 -
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
|
Phase 1 | |
Recruiting |
NCT03026140 -
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
|
Phase 2 | |
Completed |
NCT03064308 -
The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery
|
N/A | |
Active, not recruiting |
NCT02432963 -
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
|
Phase 1 | |
Active, not recruiting |
NCT04505553 -
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05672342 -
Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
|
Early Phase 1 | |
Recruiting |
NCT03334383 -
Trial for Retractor Sponge Evaluation in Laparoscopic Colorectal Surgery
|
N/A | |
Suspended |
NCT04955808 -
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
|
||
Recruiting |
NCT00922688 -
Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients
|
N/A | |
Completed |
NCT00122135 -
A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making
|
N/A |